⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277113 | 0.74 | — | — | |
| SCHEMBL9174815 | 0.73 | — | — | |
| SCHEMBL129579 | 0.71 | — | — | |
| SCHEMBL323509 | 0.69 | — | — | |
| SCHEMBL103722 | 0.69 | — | — | |
| SCHEMBL3688794 | 0.68 | — | — | |
| SCHEMBL395821 | 0.67 | MAOA (0.39) | — | |
| SCHEMBL453000 | 0.67 | — | — | |
| SCHEMBL106440 | 0.67 | ABCG2 (0.39) | — | |
| SCHEMBL3417718 | 0.65 | SMN1; SMN2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | claimed |
| EP-1830854-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | Schwarz Pharma, s.l. (ES) | 2007-09-12 | — | — | EP | claimed |
| WO-2006069993-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | SCHWARZ PHARMA S.L. (ES) | 2006-07-06 | — | — | WO | claimed |
| EP-1674103-A1 | Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands | Cepa Schwarz Pharma s.l. (ES) | 2006-06-28 | — | — | EP | claimed |
| WO-2024073042-A1 | OCULAR DELIVERY OF THERAPEUTIC AGENTS | ENTRADA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073451-A1 | MIXED VASOPRESSIN RECEPTOR AGONIST-ANTAGONIST FOR TREATING END-STAGE LIVER DISEASE AND COMPLICATIONS ASSOCIATED THEREOF | OCELOT BIO, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024054512-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4314016-A1 | CYCLIC CELL PENETRATING PEPTIDES | Entrada Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023178327-A1 | MEMBRANE TRANSLOCATION DOMAINS AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-4232020-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | Kura Oncology, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4232149-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2023-08-30 | — | — | EP | disclosed |
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | disclosed |
| EP-1976828-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Schering Aktiengesellschaft (DE) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008118790-A1 | DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008097991-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | WO | disclosed |
| EP-1830854-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | Schwarz Pharma, s.l. (ES) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007079078-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006069993-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | SCHWARZ PHARMA S.L. (ES) | 2006-07-06 | — | — | WO | disclosed |
| EP-1674103-A1 | Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands | Cepa Schwarz Pharma s.l. (ES) | 2006-06-28 | — | — | EP | disclosed |